Charles River's revenue slips on slumping R&D demand

Charles River CEO James Foster

Charles River Laboratories ($CRL) saw its sales dip in the second quarter, but the early-stage specialist is counting on some recent acquisitions to spur growth for the full year.

The Massachusetts CRO pulled in $339.6 million in revenue on the quarter, a 0.5% decrease compared to the same period last year at actual exchange rates. Accounting for the relative strength of the dollar, sales grew 5.7%, Charles River said. The company's banner research models and services business saw its revenue slide 9.8%, a decline propped up by 7.5% growth in its discovery and safety testing segment alongside a 1.1% increase in manufacturing sales.

Quarterly profits grew 35% to $49.3 million, Charles River said.

Now the CRO is increasing its full-year revenue projections, largely to account for its $212 million acquisition of the contamination testing outfit Celsis earlier this month. Charles River is expecting growth of between 3% and 4.5% for the year, amounting to about $1.3 billion. The company previously expected 1% to 2.5% growth.

Meanwhile, Charles River renewed its long-running partnership with AstraZeneca ($AZN), signing a 5-year extension to keep handling the drugmaker's safety and pharmacokinetic testing. The CRO is also planning to reopen a once-shuttered facility in Shrewsbury, MA, next year, responding to client demand for discovery services and safety tests.

- read the results

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.